reports
Treace Highlights New Product Innovations and Updated Positive Clinica...
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFA...
NCL Corporation Ltd. Announces Upsizing and Pricing of $1,300.0 Millio...
NCL Corporation Ltd. Announces Upsizing and Pricing of $1,300.0 Million of Exchangeable Notes MIAMI, Sept. 09, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it has priced $1,300.0 million aggregate principal amount of its 0.750% exchangeable senior notes due 2030 (the “Exchangeable Notes”), which were offered in a private offering (the “Exchangeable Notes Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The ...
Norwegian Cruise Line Holdings Ltd. Announces Pricing of 3,313,868 Ord...
Norwegian Cruise Line Holdings Ltd. Announces Pricing of 3,313,868 Ordinary Shares MIAMI, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) announced today that it has priced its registered direct offering of 3,313,868 ordinary shares of the Company (the “Equity Offering”) to certain holders of NCL Corporation Ltd.’s (“NCLC”), a subsidiary of the Company, 1.125% Exchangeable Senior Notes due 2027 and 2.50% Exchangeable Senior Notes due 2027 (collectively, the “2027 Exchangeable Notes”) at a price of $24.53 per share. The Equity Offering i...
NCL Corporation Ltd. Announces Pricing of $2,050.0 Million of Senior N...
NCL Corporation Ltd. Announces Pricing of $2,050.0 Million of Senior Notes MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it has priced $1,200.0 million aggregate principal amount of its 5.875% senior notes due 2031 (the “2031 Unsecured Notes”) and $850.0 million aggregate principal amount of its 6.250% senior notes due 2033 (the “2033 Unsecured Notes” and, collectively with the 2031 Unsecured Notes, the “Unsecured Notes”), which were offered in a private offering (the...
Norwegian Cruise Line Holdings Ltd. Announces Registered Direct Offeri...
Norwegian Cruise Line Holdings Ltd. Announces Registered Direct Offering of Ordinary Shares MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) announced today that it has commenced a registered direct offering of ordinary shares of the Company (the “Equity Offering”) to certain holders of NCL Corporation Ltd.’s (“NCLC”), a subsidiary of the Company, 1.125% Exchangeable Senior Notes due 2027 and 2.50% Exchangeable Senior Notes due 2027 (collectively, the “2027 Exchangeable Notes”). The Company intends to use the net proceeds from t...
NCL Corporation Ltd. Announces Debt Tender Offer
NCL Corporation Ltd. Announces Debt Tender Offer MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding (i) 5.875% Senior Secured Notes due 2027 (the “2027 Notes”) and (ii) 5.875% Senior Notes due 2026 (the “2026 Notes” and, collectively with the 2027 Notes, the “Notes” and each a “Series” of Notes). The terms and conditions of the Tender Offer are described in an Offer to Purchase dated Septembe...
NCL Corporation Ltd. Announces Proposed Offerings of Senior Notes and ...
NCL Corporation Ltd. Announces Proposed Offerings of Senior Notes and Exchangeable Notes MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it is proposing to sell $1,025.0 million aggregate principal amount of its senior notes due 2031 (the “2031 Unsecured Notes”) and $1,025.0 million aggregate principal amount of its senior notes due 2033 (the “2033 Unsecured Notes” and, collectively with the 2031 Unsecured Notes, the “Unsecured Notes”) in a private offering (the “Unsecu...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PRGO PERRIGO CO. PLC
LOB LIVE OAK BANCSHARES
GLP GLOBAL PARTNERS LP
KYN KAYNE ANDERSON MLP INVESTMENT CO.
BSM BLACK STONE MINERALS LP
EPSN EPSILON ENERGY LIMITED
DLHC DALEIGH HOLDINGS CORP
GRNT GRANIT SKOPKE
ZIP ZIPRECRUITER
HUMA INC.
MDRR HUMACYTE INC
MEDALIST DIVERSIFIED REIT INC.
Humacyte Announces Second Quarter 2025 Financial Results and Provides ...
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update - Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals - - Conference call today at 8:00 am ET - DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...
Treace Medical Concepts Reports Second Quarter 2025 Financial Results
Treace Medical Concepts Reports Second Quarter 2025 Financial Results Announces Full Market Release of Three New Bunion Technologies PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Generated revenue of $47.4 million in second quarter 2025 representing growth of 7% over the same period in...
Treace Medical to Host Investor Day Highlighting New Products on Septe...
Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025 PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technol...
Humacyte to Present Second Quarter Financial Results and Provide Corpo...
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Second Quarter 2025 Financial Results and Corporate Upda...
Treace Announces Peer-Reviewed Publication of Four-Year Results of the...
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D™ multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Proc...
Norwegian Cruise Line Holdings Reports Second Quarter 2025 Financial R...
Norwegian Cruise Line Holdings Reports Second Quarter 2025 Financial Results Company delivers record second quarter revenue, meets or exceeds all guidance metrics Reiterates full year 2025 key guidance on strength in consumer demand MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the second quarter ended June 30, 2025 and provided guidance for the third quarter and full year 2025. Highlights ...
- Jay McCanless
Treace to Report Second Quarter 2025 Financial Results on August 7, 20...
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025 PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference call to discuss financial results beginning at ...
- Dave Nicoski
- Ross LaDuke
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
NWL NEWELL BRANDS INC
NVR NVR INC.
LEN LENNAR CORPORATION CLASS A
KHC KRAFT HEINZ COMPANY
KBH KB HOME
JACK JACK IN THE BOX INC.
HD HOME DEPOT INC.
CHDN CHURCHILL DOWNS INCORPORATED
CCS CENTURY COMMUNITIES INC.
CAL CALERES INC.
AEO AMERICAN EAGLE OUTFITTERS INC.
DHI D.R. HORTON INC.
BC BRUNSWICK CORPORATION
CRI CARTER'S INC.
GES GUESS? INC.
LEG LEGGETT & PLATT INCORPORATED
SCVL SHOE CARNIVAL INC.
CARS CARS.COM INC.
FT FRANKLIN UNIVERSAL TRUST
MRNA MODERNA INC.
EMBC EMBECTA CORP
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
Humacyte Announces First Symvess™ Sale to Military Treatment Facility Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a state-of...
- Wedbush Research
RWT REDWOOD TRUST INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
PEB PEBBLEBROOK HOTEL TRUST
O REALTY INCOME CORPORATION
NHI NATIONAL HEALTH INVESTORS INC.
LTC LTC PROPERTIES INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
APLE APPLE HOSPITALITY REIT INC
HST HOST HOTELS & RESORTS INC.
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VICI VICI PROPERTIES INC
EPRT ESSENTIAL PROPERTIES REALTY TRUST
RC READY CAPITAL CORPORATION
NTST NETSTREIT CORP
STRW STRAWBERRY FIELDS REIT INC.
BNL BROADSTONE NET LEASE INC
Leggett & Platt Announces 2Q 2025 Earnings Call
Leggett & Platt Announces 2Q 2025 Earnings Call Carthage, MO, July 17, 2025 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release second quarter earnings results on Thursday, July 31, 2025 after the market closes, and hold its quarterly conference call to discuss second quarter results, annual guidance, market conditions, company initiatives, and related matters on Friday, August 1, 2025, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call will be webcast and can be accessed from the Investo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.